Theralase Research Shows RuvidarTM More Effective Than Acyclovir on HSV

Theralase Technologies Inc. has announced that research from the University of Manitoba found RuvidarTM significantly outperforms acyclovir in inactivating Herpes Simplex Viruses (HSV) post-infection. This new study confirms RuvidarTM's efficacy, both with and without light activation, showing it can inhibit HSV replication at lower concentrations compared to acyclovir.

RuvidarTM, when combined with acyclovir, demonstrates synergistic effects on HSV-1, further underscoring its potential as a therapeutic agent. Kevin Coombs, leading the study, was impressed by RuvidarTM's performance, suggesting a promising future for its application in HSV treatments. Theralase is now moving towards developing vaccines and therapeutics based on these findings.

The pharmaceutical company foresees employing RuvidarTM as a foundation for tackling viral infections and pandemics. With preclinical development underway, Theralase plans to pioneer clinical trials soon.